Systemic anthrax following inhalation exposure poses a severe management challenge in neonates. This protocol covers empiric treatment for preterm and full-term newborns at 32 to 44 weeks postmenstrual age — defined as gestational age plus chronologic age — presenting with systemic anthrax (inhalation/pulmonary), with or without concurrent meningitis.
Neonates at 32 to 44 weeks postmenstrual age (gestational age plus chronologic age) with systemic anthrax (inhalation/pulmonary), with or without meningitis. Treatment considerations are stratified by both gestational age subgroup and chronologic age within this population.
The preferred strategy is combination therapy: two bactericidal agents from different antimicrobial classes, together with a protein synthesis inhibitor or RNA inhibitor, plus a single antitoxin as adjunctive therapy. Treatment duration is 2 weeks or longer; transition from intravenous to oral administration is guided by patient improvement and clinical judgment. The complete regimen, drug selection, and age-stratified considerations are available in the full protocol.
For preterm and full-term newborns 32–44 weeks' postmenstrual age (i.e., gestational age plus chronologic age), empiric treatment regimens for those with systemic anthrax with or without meningitis (Table 17) are summarized as follows:
Antimicrobial drugs: Choose two bactericidal drugs from different antimicrobial drug classes plus a PSI or an RNAI.
Antitoxin: Choose a single antitoxin as adjunctive therapy.
Duration of antimicrobial drug treatment should be for 2 weeks or longer, although as immune-compromised hosts, neonates might require a longer duration of therapy to achieve cure.
Transition from IV administration to oral medication for neonates tolerating regular feeding should be based on patient improvement and clinical judgment.
View source ↗